A Podcast Hosted by Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES & Natalie Bellini, DNP, FNP-BC
in association with
A Podcast Hosted by Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES & Natalie Bellini, DNP, FNP-BC
in association with
Featured Episodes
The impact of stigma and lack of patient-centric language impacts healthcare at both an individual and population level, with this true across a host of conditions, but particularly true among people with diabetes.
At the 83rd Scientific Sessions of the American Diabetes Association (ADA 2023), Jane Dickinson, RN, PhD, program director and senior lecturer at Teachers College of Columbia University, has taken aim at addressing both of these topics.Â
As a follow-up to an episode from earlier this year with Beta Bionics’s chief medical officer Stephen Russell, MD, and the FDA clearances of the technology that forms the iLet Bionic Pancreas, Diana Isaacs, PharmD, an endocrine clinical pharmacist and coordinator of the Remote Monitoring Program at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, sat down in the MJH Life Sciences studio for a special edition recording of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives. In the episode, hosts explore the implications of the clearance, dispel misconceptions surrounding the system, and hypothesize about the future of this technology in people with diabetes.
In this special edition episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist and coordinator of the Remote Monitoring Program at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, sit down for an in-depth discussion surrounding the new algorithms and break down what and how they expect the new guidance to impact patient care.
In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, Robert Vigersky, MD, chief medical officer of Medtronic Diabetes, sits down to provide a comprehensive overview of the system, the advantages it provides to patients, plans for nationwide rollout, and more. Later in the episode, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist and coordinator of the Remote Monitoring Program at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, dive deeper into what the approval means for patients, with a focus on the accessibility of the system for users.
The impact of stigma and lack of patient-centric language impacts healthcare at both an individual and population level, with this true across a host of conditions, but particularly true among people with diabetes.
At the 83rd Scientific Sessions of the American Diabetes Association (ADA 2023), Jane Dickinson, RN, PhD, program director and senior lecturer at Teachers College of Columbia University, has taken aim at addressing both of these topics. At the meeting, Dickinson served as chair for an oral presentation session with a theme of expanding the delivery and perception of diabetes self-management education.
As a follow-up to an episode from earlier this year with Beta Bionics’s chief medical officer Stephen Russell, MD, and the FDA clearances of the technology that forms the iLet Bionic Pancreas, Diana Isaacs, PharmD, an endocrine clinical pharmacist and coordinator of the Remote Monitoring Program at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, sat down in the MJH Life Sciences studio for a special edition recording of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives. In the episode, hosts explore the implications of the clearance, dispel misconceptions surrounding the system, and hypothesize about the future of this technology in people with diabetes.
In this special edition episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist and coordinator of the Remote Monitoring Program at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, sit down for an in-depth discussion surrounding the new algorithms and break down what and how they expect the new guidance to impact patient care.
In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, Robert Vigersky, MD, chief medical officer of Medtronic Diabetes, sits down to provide a comprehensive overview of the system, the advantages it provides to patients, plans for nationwide rollout, and more. Later in the episode, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist and coordinator of the Remote Monitoring Program at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, dive deeper into what the approval means for patients, with a focus on accessibility of the system for users.